Menu Search
Equities

Ibio Inc

0JV:DEU

Ibio Inc

Actions
  • Price (EUR)0.70
  • Today's Change-0.055 / -7.28%
  • Shares traded1.92k
  • 1 Year change-87.72%
  • Beta--
Data delayed at least 15 minutes, as of May 26 2023 20:43 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

iBio, Inc. is a developer of next-generation biopharmaceuticals using its proprietary artificial intelligence (AI)-Driven Discovery Platform and FastPharming Manufacturing System. The Company is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The Company through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The Company operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.

  • Revenue in USD (TTM)61.00k
  • Net income in USD-41.43m
  • Incorporated2008
  • Employees105.00
  • Location
    Ibio Inc600 Madison Avenue, Suite 1601NEW YORK 10022-1737United StatesUSA
  • Phone+1 (302) 355-0650
  • Fax+1 (302) 356-1173
  • Websitehttps://www.ibioinc.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		IBIO:ASQ since
announced		Transaction
value
Rubryc Therapeutics IncDeal completed21 Sep 202221 Sep 2022Deal completed-91.15%6.00m
Data delayed at least 15 minutes, as of May 26 2023 21:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.